American Journal of Kidney Diseases

Wormwood (Artemisia absinthium) for Poorly Responsive Early-Stage IgA Nephropathy: A Pilot Uncontrolled Trial

Published:September 15, 2010DOI:


      Inhibition of the renin-angiotensin system is a widely accepted approach to treat immunoglobulin A (IgA) nephropathy, whereas the role of fish oils as a supplement is controversial. Tumor necrosis factor α (TNF-α) is considered to be involved in the pathophysiologic process of this disorder. Recent in vitro and clinical observations that wormwood can decrease TNF-α levels has led us to investigate the effect of wormwood as a supplement in patients with IgA nephropathy.

      Study Design

      Pilot uncontrolled trial.

      Setting & Participants

      10 patients with biopsy-proven IgA nephropathy, normal kidney function, and a history of at least 3 months of proteinuria with protein excretion >500 mg/d and <3,500 mg/d despite ongoing dual renin-angiotensin system blockade.


      The selected patients were given supplements of 1.8 g/d of thujone-free wormwood preparation for 6 months without discontinuing their renin-angiotensin system blockade.


      Proteinuria and blood pressure after intervention compared with baseline values.


      Monthly assessment of urine protein-creatinine ratio and blood pressure during the observation period.


      Urine protein-creatinine ratio decreased significantly from 2,340 ± 530 to 315 ± 200 mg/g at the end of the supplementation period (P < 0.001) and was stable during the supplement-free follow-up of another 6 months. Estimated glomerular filtration rate and endogenous creatinine clearance were unchanged during the entire study period. There was a moderate, but significant, decrease (P < 0.002) in mean arterial blood pressure.


      Open uncontrolled trial including a small number of patients.


      Thujone-free wormwood with its favorable safety profile can be an alternative supplement to manage proteinuria in patients with IgA nephropathy.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reich H.N.
        • Troyanov S.
        • Scholey J.W.
        • Cattran D.C.
        Remission of proteinuria improves prognosis in IgA nephropathy.
        J Am Soc Nephrol. 2007; 18: 3177-3183
        • MacKinnon M.
        • Shurraw S.
        • Akbari A.
        • Knoll G.
        • Jaffey J.
        • Clark H.
        Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
        Am J Kidney Dis. 2009; 48: 8-20
        • Dillon J.J.
        Fish oil therapy for IgA nephropathy: efficacy and interstudy variability.
        J Am Soc Nephrol. 1997; 8: 1739-1744
        • Yu L.F.
        • Chen X.M.
        • Bo L.Q.
        Tumor necrosis factor alpha in IgA nephropathy.
        Zhonghua Nei Ke Za Zhi. 1993; 32: 322-323
        • Lai K.N.
        • Leung J.C.
        • Chan L.Y.
        • et al.
        Activation of podocytes by mesangial-derived TNF-α glomerulo-podocytic communication in IgA nephropathy.
        Am J Physiol Renal Physiol. 2008; 294: F945-F955
        • Chan L.Y.
        • Leung J.C.
        • Tsng A.W.
        • Tang S.C.
        • Lai K.N.
        Activation of tubular epithelial cells by mesangial-derived TNF-α glomerulo-tubular communication in IgA nephropathy.
        Kidney Int. 2005; 67: 602-612
        • Leung J.C.
        • Tang S.C.
        • Chan L.Y.
        • Lai K.N.
        Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA—role of MAPK and NF-kappaB.
        Nephrol Dial Transplant. 2008; 23: 72-81
        • Sakellariou G.T.
        • Vounotrypidis P.
        • Berberidis C.
        Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy.
        Clin Rheumatol. 2007; 26: 1132-1133
        • Koo H.N.
        • Hong S.H.
        • Jeong H.J.
        • et al.
        Inhibitory effect of Artemisia capillaris on ethanol-induced cytokines (TNF-alpha, IL-1alpha) secretion in Hep G2 cells.
        Immunopharmacol Immunotoxicol. 2002; 24: 441-453
        • Lee H.G.
        • Kim H.
        • Oh W.K.
        • et al.
        Tetramethoxy hydroxyflavone p7F down-regulates inflammatory mediators via the inhibition of nuclear factor kappaB.
        Ann N Y Acad Sci. 2004; 1030: 555-568
        • Krebs S.
        • Omer T.N.
        • Omer B.
        Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease—a controlled trial.
        Phytomedicine. 2010; 17: 305-309
        • Omer B.
        • Krebs S.
        • Omer H.
        • Noor T.O.
        Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study.
        Phytomedicine. 2007; 14: 87-95
        • Khan I.A.
        • Abourashed E.A.
        Encyclopaedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics. 2nd ed. John Wiley & Sons, New York, NY1996: 1-3
        • Kern W.
        • Roth H.J.
        • Schmidt W.
        Artemisia absinthium.
        in: List P.H. Hoerhammer L. Hager's Handbuch der Pharmazeutischen Praxis für Apotheker, Arzneimittelhersteller, ärzte und Medizinalbeamte. Vol 3. Springer-Verlag, Berlin, Germany1973: 254-259
        • Muto T.
        • Watanabe T.
        • Okamura M.
        • Moto M.
        • Kashida Y.
        • Mitsumori K.
        Thirteen-week repeated dose toxicity study of wormwood (Artemisia absinthium) extract in rats.
        J Toxicol Sci. 2004; 28: 471-478
        • Kuester S.
        • Mehls O.
        • Seidel C.
        • Ritz E.
        Blood pressure in minimal change and other types of nephrotic syndrome.
        Am J Nephrol. 1990; 10: 76-80
        • MacDonald N.
        Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care.
        J Support Oncol. 2007; 5: 157-162
        • Hatziieremia S.
        • Gray A.I.
        • Ferro V.
        • Paul A.
        • Plevin R.
        The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFB signalling pathways in monocytes/macrophages.
        Br J Pharmacol. 2006; 149: 188-198
        • Lee J.H.
        • Jung H.S.
        • Giang P.M.
        • et al.
        Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera.
        J Pharmacol Exp Ther. 2006; 316: 271-277